Title:
IRTA-4 ANTIBODIES AND THEIR USES
Document Type and Number:
WIPO Patent Application WO2006039135
Kind Code:
A3
Abstract:
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-4 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-4, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.
Inventors:
SRINIVASAN MOHAN (US)
CARDARELLI JOSEPHINE M (US)
HUANG HAICHUN (US)
CARDARELLI JOSEPHINE M (US)
HUANG HAICHUN (US)
Application Number:
PCT/US2005/033514
Publication Date:
August 17, 2006
Filing Date:
September 19, 2005
Export Citation:
Assignee:
MEDAREX INC (US)
SRINIVASAN MOHAN (US)
CARDARELLI JOSEPHINE M (US)
HUANG HAICHUN (US)
SRINIVASAN MOHAN (US)
CARDARELLI JOSEPHINE M (US)
HUANG HAICHUN (US)
International Classes:
C07K16/00; A01K67/027; A61K39/395; C07H21/04; C12N5/06; C12N15/00; C12P21/06; C12Q1/68
Domestic Patent References:
| WO2001038490A2 | 2001-05-31 |
Other References:
REFF M. E, HEARD C.: "A review of modifications to recobinant antibodies: attempt to increase efficacy in oncology applications", CRITICAL REVIEWS IN ONOLOGY/HEMATOLOGY, vol. 40, no. 1, October 2001 (2001-10-01), pages 25 - 35, XP002329383
Download PDF: